For research use only. Not for use in humans.

Romosozumab(anti-sclerostin)

Cat.No.A2050 Purity:99%

Romosozumab is a monoclonal antibody that binds to sclerostin (an inhibitor of the Wingless-related integration site (Wnt) signaling pathway). It is a new osteoanabolic drug, that simultaneously increases bone formation and decreases bone resorption.

Quality Control

Batch: Purity: 99% Protein concentration: 7.92mg/ml Endotoxin Level: ＜1EU/mg

Mechanism of Action

Description	Romosozumab is a monoclonal antibody that binds to sclerostin (an inhibitor of the Wingless-related integration site (Wnt) signaling pathway). It is a new osteoanabolic drug, that simultaneously increases bone formation and decreases bone resorption.
References	[1] https://pubmed.ncbi.nlm.nih.gov/36440489/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	909395-70-6
Molecular Weight	150 kDa
Isotype	human IGg2, κ
Application	Romosozumab(anti-sclerostin)
Purification	Protein G
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20 mM Arg, pH 5.0
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.